Literature DB >> 8798100

Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction.

M F Rousseau1, F Chapelle, C Van Eyll, L Stoleru, D Hager, L Van Nueten, H Pouleur.   

Abstract

The aim of this study was to compare the effects on left ventricular function and exercise tolerance of a selective beta-antagonist (atenolol) with those of another selective beta 1-antagonist with vasodilator properties (nebivolol) in patients with ischemic left ventricular dysfunction but no overt congestive heart failure. Beta blockers are widely used in ischemic heart disease, but their effects on left ventricular mechanics and exercise tolerance are poorly defined in the subgroup of patients with significant systolic dysfunction but without clinical evidence of ischemia or congestive heart failure. Angiographic and symptom-limited exercise data were obtained at baseline and after an 8-10-week double-blind treatment with placebo (n = 10), 50 mg atenolol daily (n = 10), or 2.5 mg (n = 10) or 5 mg (n = 10) nebivolol daily. When compared to placebo, both atenolol and nebivolol reduced resting heart rate and improved left ventricular ejection fraction (from 33.9 to 39.2% with atenolol and from 36.5 to 40.8% with nebivolol, both P < .05) while lowering mean systolic wall stress. Only nebivolol, however, produced a parallel downward shift of the pressure-volume relationship during early diastolic filling and improved the early peak filling rate when compared to placebo (+ 10%, P < .05). When compared to baseline, maximal exercise duration increased by 7 and 13 seconds with placebo and atenolol, respectively (both NS vs baseline), and increased by 44 seconds with nebivolol (P = .0077 vs baseline). Both atenolol and nebivolol decreased maximal exercise heart rate; the reduction was more pronounced with atenolol. Prolonged beta 1-adrenoceptor blockade leads to a significant increase in left ventricular ejection fraction in patients with ischemic left ventricular dysfunction. The dissociation between the changes in resting left ventricular function and the changes in exercise duration suggests that in this clinical setting, the changes in systolic function may have less impact on functional capacity than an improvement in diastolic distensibility during the rapid filling phase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798100     DOI: 10.1016/s1071-9164(96)80004-2

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  10 in total

Review 1.  Drugs, heart failure and quality of life: what are we achieving? What should we be trying to achieve?

Authors:  N Doba; H Tomiyama; T Nakayama
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  [Hemodynamic effects of the beta blocker nebivolol].

Authors:  S Rosenkranz; E Erdmann
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

3.  Pharmacological properties of nebivolol in man.

Authors:  L M Van Bortel; J N de Hoon; M J Kool; J A Wijnen; C I Vertommen; L G Van Nueten
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 4.  Nebivolol in the management of essential hypertension: a review.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 5.  Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents.

Authors:  Andrew J S Coats
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 6.  Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure.

Authors:  Donatella Del Sindaco; Maria Denitza Tinti; Luca Monzo; Giovanni Pulignano
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458

7.  Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.

Authors:  Valerio Zacà; Sharad Rastogi; Sudhish Mishra; Mengjun Wang; Victor G Sharov; Ramesh C Gupta; Sidney Goldstein; Hani N Sabbah
Journal:  Cardiology       Date:  2008-10-02       Impact factor: 1.869

8.  Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.

Authors:  Otto Kamp; Marco Metra; Silvia Bugatti; Luca Bettari; Alessandra Dei Cas; Natalia Petrini; Livio Dei Cas
Journal:  Drugs       Date:  2010       Impact factor: 9.546

Review 9.  Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.

Authors:  Robert Weiss
Journal:  Vasc Health Risk Manag       Date:  2006

10.  Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction.

Authors:  Mehmet Ozaydin; Habil Yucel; Sule Kocyigit; Mehmet Koray Adali; Fatih Aksoy; Fatih Kahraman; Bayram Ali Uysal; Dogan Erdogan; Ercan Varol; Abdullah Dogan
Journal:  Med Princ Pract       Date:  2016-05-10       Impact factor: 1.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.